Sign In
Buy COYA
$4.64
-0.0900 (-1.90%)
At Close: Jun 03, 2026
Coya Therapeutics to Present ALSTARS Trial Design at the 5th ALS Drug Development Summit
08:00am, Wednesday, 27'th May 2026
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance T-cell (Treg) functi
Coya Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update
07:35am, Tuesday, 12'th May 2026
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance T-cell (Treg) functi
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cel
Coya Therapeutics, Inc. (NASDAQ:COYA) Receives Consensus Rating of “Moderate Buy” from Brokerages
04:10am, Saturday, 18'th Apr 2026
Shares of Coya Therapeutics, Inc. (NASDAQ: COYA - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the six analysts that are covering the stock, Marketbeat reports. One in
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance Treg function, annou
Coya Therapeutics Announces Planned Board Transition and Appointment of Mark H. Pavao as Independent Director
08:00am, Thursday, 02'nd Apr 2026
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance T-cell (Treg) functi
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance Treg function, annou
Coya Therapeutics Provides a Corporate Update and Reports Fiscal 2025 Financial Results
08:00am, Monday, 16'th Mar 2026
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance T-cell (Treg) functi
Coya Therapeutics (COYA) to Release Quarterly Earnings on Tuesday
02:30am, Tuesday, 10'th Mar 2026
Coya Therapeutics (NASDAQ: COYA - Get Free Report) is projected to announce its Q4 2025 results before the market opens on Tuesday, March 17th. Analysts expect the company to announce earnings of ($0.
Coya Therapeutics, Inc. (COYA) Upgraded to Buy: What Does It Mean for the Stock?
01:01pm, Wednesday, 25'th Feb 2026
Coya Therapeutics, Inc. (COYA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Coya Therapeutics Details ALS Combo Immunotherapy Plan, Highlights Early Biomarker Signals in Webinar
04:07am, Thursday, 19'th Feb 2026
Speakers on a Coya Therapeutics (NASDAQ: COYA) webinar outlined the company's scientific rationale and clinical development plans for an investigational combination immunotherapy in amyotrophic latera
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance T-cell (Treg) functi
Coya Therapeutics Announces $11.1 Million Private Placement
08:00am, Friday, 30'th Jan 2026
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (Nasdaq: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cel
Coya Therapeutics CEO Dr. Arun Swaminathan Issues Letter to Stockholders
08:00am, Tuesday, 20'th Jan 2026
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance Treg function, relea
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cel
